Skip to main content
. 2023 Oct 17;193(3):426–453. doi: 10.1093/aje/kwad201

Table 1.

Characteristics of the Included Studies in the Scoping Review for the State of Use and Utility of Negative Controls in Pharmacoepidemiologic Studies

Characteristic Study (n = 184)
No. %
 Publication year
  Before 2012 12 6.5
  2013–2016 46 25.0
  2017–2020 126 68.5
 Study region
  North America 94 51.1
  Europe 61 33.2
  Asia 13 7.1
  Others 4 2.2
  Multiple regions (including more than 1 continent) 12 6.4
 Study design
  Cohort study 115 62.5
  Case-control study 12 6.5
  Self-controlled case series 9 4.9
  Nested case-control study 7 3.8
  Ecological study 5 2.7
  Self-controlled cohort study 2 1.1
  Case-crossover study 1 0.5
  Cross-sectional study 1 0.5
  Self-controlled risk interval study 1 0.5
  Pharmacovigilance study
   Disproportionality analysis 4 2.2
   Sequence symmetry analysis 3 1.6
  Sequential statistical testing 3 1.6
  Multiple studies with different designs/methods 14 7.6
  Reference set identification 5 2.7
  Others 2 1.1
 Type of NC
  NCE 54 29.3
  NCO 91 49.5
  Both NCE and NCO 34 18.5
  Not applicablea 5 2.7
 No. of NCs used
  Single (either NCE or NCO) 84 45.7
  Multiple 94 51.0
  Not applicablea/not reported 6 3.3
 Type of biasb
  Unmeasured confounding 93 50.5
  Information bias (e.g., misclassification, measurement error) 10 5.4
  Selection bias 7 3.8
  Protopathic bias 2 1.1
  Bias in general/not specified 80 43.5
 Type of data source usedb
  Health-care administrative data (e.g., insurance claims, national health system data) 114 62.0
  Electronic health records 61 33.2
  Research data (e.g., primary data) 26 14.1
  Disease registry 11 6.0
  Passive surveillance data for drug safety 7 3.8
  Simulated data set 6 3.3
  Public health survey data 4 2.2
  Not applicablea 5 2.7

Abbreviations: NC, negative control; NCE, negative control exposure; NCO, negative control outcome.

a Reference set identification studies with no empirical application of NC.

b Categories are not mutually exclusive.